Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion

Journal of Molecular and Cellular Cardiology

Volumn 100, Issue , 2016, Pages 64-71

  Choi, Yong Seon ^a   de Mattos, Ana Barbosa Marcondes ^a   Shao, Dan ^a   Li, Tao ^a   Nabben, Miranda ^a   Kim, Maengjo ^a   Wang, Wang ^a   Tian, Rong ^a   Kolwicz, Stephen C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ACC2; Cardiac metabolism; Hypertrophy; Lipids; Myocardium

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE 2; ACONITATE HYDRATASE; ATP SYNTHASE SUBUNIT ALPHA; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARBONYL DERIVATIVE; CITRATE SYNTHASE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 2; CONNECTIVE TISSUE GROWTH FACTOR; CYTOCHROME B; CYTOCHROME C; CYTOCHROME C OXIDASE; ESTROGEN RELATED RECEPTOR ALPHA; HYDROGEN PEROXIDE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RNA 16S; SUCCINATE DEHYDROGENASE (UBIQUINONE); TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACACB PROTEIN, MOUSE; ANGIOTENSIN II; FATTY ACID;

ADULT; ANAPLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ENZYME ACTIVITY; ENZYME METABOLISM; FATTY ACID OXIDATION; GENE DELETION; GENE EXPRESSION; GLYCOLYSIS; HEART EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; MALE; METABOLIC PARAMETERS; MITOCHONDRIAL BIOGENESIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY CHAIN; UPREGULATION; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; DEFICIENCY; DIASTOLE; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FIBROSIS; GENETICS; HEART VENTRICLE FUNCTION; KNOCKOUT MOUSE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANELLE BIOGENESIS; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; ULTRASTRUCTURE;

ACETYL-COA CARBOXYLASE; ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; DIASTOLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FATTY ACIDS; FIBROSIS; GENE DELETION; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; ORGANELLE BIOGENESIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; VENTRICULAR DYSFUNCTION;

EID: 84992184176     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.09.001     Document Type: Article

References (49)

1. [1] Bui, A.L., Horwich, T.B., Fonarow, G.C., Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8 (2011), 30–41.
2. [2] Owan, T.E., Redfield, M.M., Epidemiology of diastolic heart failure. Prog. Cardiovasc. Dis. 47 (2005), 320–332.
3. [3] Borlaug, B.A., Redfield, M.M., Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123 (2011), 2006–2013 (discussion 14).
4. [4] Andersen, M.J., Borlaug, B.A., Heart failure with preserved ejection fraction: current understandings and challenges. Curr. Cardiol. Rep., 16, 2014, 501.
5. [5] Shah, A.M., Shah, S.J., Anand, I.S., Sweitzer, N.K., O'Meara, E., Heitner, J.F., et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ. Heart Fail. 7 (2014), 104–115.
6. [6] Zile, M.R., Gottdiener, J.S., Hetzel, S.J., McMurray, J.J., Komajda, M., McKelvie, R., et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 (2011), 2491–2501.
7. [7] Borlaug, B.A., Redfield, M.M., Melenovsky, V., Kane, G.C., Karon, B.L., Jacobsen, S.J., et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ. Heart Fail. 6 (2013), 944–952.
8. [8] Kane, G.C., Karon, B.L., Mahoney, D.W., Redfield, M.M., Roger, V.L., Burnett, J.C. Jr., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306 (2011), 856–863.
9. [9] Chiao, Y.A., Kolwicz, S.C., Basisty, N., Gagnidze, A., Zhang, J., Gu, H., et al. Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts. Aging (Albany NY) 8 (2016), 314–327.
10. [10] Kolwicz, S.C. Jr., Olson, D.P., Marney, L.C., Garcia-Menendez, L., Synovec, R.E., Tian, R., Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ. Res. 111 (2012), 728–738.
11. [11] De Mello, W.C., Danser, A.H., Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 35 (2000), 1183–1188.
12. [12] Xu, Z., Okamoto, H., Akino, M., Onozuka, H., Matsui, Y., Tsutsui, H., Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J. Cardiovasc. Pharmacol. 51 (2008), 62–70.
13. [13] Mori, J., Basu, R., McLean, B.A., Das, S.K., Zhang, L., Patel, V.B., et al. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ. Heart Fail. 5 (2012), 493–503.
14. [14] Dai, D.F., Johnson, S.C., Villarin, J.J., Chin, M.T., Nieves-Cintron, M., Chen, T., et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ. Res. 108 (2011), 837–846.
15. [15] Garcia-Menendez, L., Karamanlidis, G., Kolwicz, S., Tian, R., Substrain specific response to cardiac pressure overload in C57BL/6 mice. Am. J. Physiol. Heart Circ. Physiol. 305 (2013), H397–H402.
16. 31P NMR Spectroscopy. 2010, Journal of visualized experiments, JoVE.
17. [17] Kolwicz, S.C. Jr., Liu, L., Goldberg, I.J., Tian, R., Enhancing cardiac triacylglycerol metabolism improves recovery from ischemic stress. Diabetes 64 (2015), 2817–2827.
18. [18] Spinazzi, M., Casarin, A., Pertegato, V., Salviati, L., Angelini, C., Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat. Protoc. 7 (2012), 1235–1246.
19. [19] Dikalov, S.I., Nazarewicz, R.R., Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid. Redox Signal. 19 (2013), 1085–1094.
20. [20] Frohnert, B.I., Bernlohr, D.A., Protein carbonylation, mitochondrial dysfunction, and insulin resistance. Adv. Nutr. 4 (2013), 157–163.
21. [21] Sadek, H.A., Humphries, K.M., Szweda, P.A., Szweda, L.I., Selective inactivation of redox-sensitive mitochondrial enzymes during cardiac reperfusion. Arch. Biochem. Biophys. 406 (2002), 222–228.
22. [22] Yan, L.J., Levine, R.L., Sohal, R.S., Oxidative damage during aging targets mitochondrial aconitase. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 11168–11172.
23. [23] Larkin, J.E., Frank, B.C., Gaspard, R.M., Duka, I., Gavras, H., Quackenbush, J., Cardiac transcriptional response to acute and chronic angiotensin II treatments. Physiol. Genomics 18 (2004), 152–166.
24. [24] Akki, A., Smith, K., Seymour, A.M., Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol. Cell. Biochem. 311 (2008), 215–224.
25. [25] Young, M.E., Laws, F.A., Goodwin, G.W., Taegtmeyer, H., Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276 (2001), 44390–44395.
26. [26] Allard, M.F., Schonekess, B.O., Henning, S.L., English, D.R., Lopaschuk, G.D., Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Phys. 267 (1994), H742–H750.
27. [27] Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A., Kelly, D.P., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996), 2837–2842.
28. [28] Aubert, G., Martin, O.J., Horton, J.L., Lai, L., Vega, R.B., Leone, T.C., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
29. [29] Chokshi, A., Drosatos, K., Cheema, F.H., Ji, R., Khawaja, T., Yu, S., et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125 (2012), 2844–2853.
30. [30] Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A., et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
31. [31] Kuznetsova, T., Herbots, L., Lopez, B., Jin, Y., Richart, T., Thijs, L., et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ. Heart Fail. 2 (2009), 105–112.
32. [32] Lamb, H.J., Beyerbacht, H.P., van der Laarse, A., Stoel, B.C., Doornbos, J., van der Wall, E.E., et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99 (1999), 2261–2267.
33. [33] Tian, R., Nascimben, L., Ingwall, J.S., Lorell, B.H., Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96 (1997), 1313–1319.
34. [34] Serneri, G.G., Boddi, M., Cecioni, I., Vanni, S., Coppo, M., Papa, M.L., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ. Res. 88 (2001), 961–968.
35. [35] Mori, J., Zhang, L., Oudit, G.Y., Lopaschuk, G.D., Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. J. Mol. Cell. Cardiol. 63 (2013), 98–106.
36. [36] de Cavanagh, E.M., Ferder, M., Inserra, F., Ferder, L., Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am. J. Physiol. Heart Circ. Physiol. 296 (2009), H550–H558.
37. [37] Mori, J., Alrob, O.A., Wagg, C.S., Harris, R.A., Lopaschuk, G.D., Oudit, G.Y., ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am. J. Physiol. Heart Circ. Physiol. 304 (2013), H1103–H1113.
38. [38] Chiu, H.C., Kovacs, A., Ford, D.A., Hsu, F.F., Garcia, R., Herrero, P., et al. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107 (2001), 813–822.
39. [39] He, L., Kim, T., Long, Q., Liu, J., Wang, P., Zhou, Y., et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126 (2012), 1705–1716.
40. [40] Russo, S.B., Baicu, C.F., Van Laer, A., Geng, T., Kasiganesan, H., Zile, M.R., et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J. Clin. Invest. 122 (2012), 3919–3930.
41. [41] Jarreta, D., Orus, J., Barrientos, A., Miro, O., Roig, E., Heras, M., et al. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc. Res. 45 (2000), 860–865.
42. [42] Marin-Garcia, J., Goldenthal, M.J., Moe, G.W., Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc. Res. 52 (2001), 103–110.
43. [43] Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J.J., Hu, X.X., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56 (2007), 2457–2466.
44. [44] Vincent, H.K., Powers, S.K., Dirks, A.J., Scarpace, P.J., Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int. J. Obes. Relat. Metab. Disord. 25 (2001), 378–388.
45. [45] Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90 (2010), 207–258.
46. [46] Schonfeld, P., Wieckowski, M.R., Lebiedzinska, M., Wojtczak, L., Mitochondrial fatty acid oxidation and oxidative stress: lack of reverse electron transfer-associated production of reactive oxygen species. Biochim. Biophys. Acta 2010 (1797), 929–938.
47. [47] Fragasso, G., Rosano, G., Baek, S.H., Sisakian, H., Di Napoli, P., Alberti, L., et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int. J. Cardiol. 163 (2013), 320–325.
48. [48] Kantor, P.F., Lucien, A., Kozak, R., Lopaschuk, G.D., The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86 (2000), 580–588.
49. [49] Lionetti, V., Linke, A., Chandler, M.P., Young, M.E., Penn, M.S., Gupte, S., et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc. Res. 66 (2005), 454–461.